About Impax Laboratories (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:IPXL
CUSIP45256B10
Phone510-476-2000
Debt
Debt-to-Equity Ratio4.11%
Current Ratio1.96%
Quick Ratio1.52%
Price-To-Earnings
Trailing P/E Ratio32.06
Forward P/E Ratio16.69
P/E Growth0.88
Sales & Book Value
Annual Sales$775.79 million
Price / Sales1.92
Cash Flow$2.1398 per share
Price / Cash9.44
Book Value$2.53 per share
Price / Book7.98
Profitability
EPS (Most Recent Fiscal Year)$0.63
Net Income$-469,280,000.00
Net Margins-60.49%
Return on Equity10.42%
Return on Assets2.83%
Miscellaneous
Employees1,257
Outstanding Shares73,870,000
Impax Laboratories (NASDAQ:IPXL) Frequently Asked Questions
What is Impax Laboratories' stock symbol?
Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."
How were Impax Laboratories' earnings last quarter?
Impax Laboratories Inc (NASDAQ:IPXL) released its quarterly earnings data on Thursday, March, 1st. The specialty pharmaceutical company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by $0.01. The specialty pharmaceutical company earned $182.90 million during the quarter, compared to analysts' expectations of $199.13 million. Impax Laboratories had a negative net margin of 60.49% and a positive return on equity of 10.42%. The firm's quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.16 EPS. View Impax Laboratories' Earnings History.
When is Impax Laboratories' next earnings date?
What price target have analysts set for IPXL?
15 brokers have issued twelve-month price objectives for Impax Laboratories' shares. Their forecasts range from $16.00 to $35.00. On average, they expect Impax Laboratories' stock price to reach $21.7333 in the next year. View Analyst Ratings for Impax Laboratories.
What are Wall Street analysts saying about Impax Laboratories stock?
Here are some recent quotes from research analysts about Impax Laboratories stock:
- 1. According to Zacks Investment Research, "Impax missed estimates for both the counts in the fourth quarter of 2017. The company faces competition in the brand product market from Parkinson’s disease and CNS disorder focused large pharmaceutical companies. Impax’s Generics segment underperformed in 2017, due to significant pricing erosion complemented by erosion in volume. However, the company’s epinephrine auto-injector sales have picked up. Meanwhile, Impax is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. Shares of the company outperformed the industry in a year’s time." (3/27/2018)
- 2. Cantor Fitzgerald analysts commented, "IPXL announced this morning that Robert Stewart will be joining the company as CEO, effective January 25, 2018." (12/15/2017)
Who are some of Impax Laboratories' key competitors?
Some companies that are related to Impax Laboratories include Clovis Oncology (CLVS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY), Puma Biotechnology (PBYI), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), AnaptysBio (ANAB) and Intercept Pharmaceuticals (ICPT).
Who are Impax Laboratories' key executives?
Impax Laboratories' management team includes the folowing people:
- Robert L. Burr, Independent Chairman of the Board (Age 66)
- Paul M. Bisaro, President, Chief Executive Officer, Director (Age 56)
- Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance (Age 49)
- Douglas S Boothe, President - Generics Division (Age 53)
- Michael J. Nestor, President - Impax Specialty Pharmaceutical Division (Age 64)
- Robert A. Stewart, President of Amneal (Age 50)
- Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary (Age 56)
- Jeffrey D. Nornhold, Senior Vice President - Technical Operations (Age 51)
- J. Kevin Buchi, Director (Age 61)
- Janet S Vergis, Director (Age 52)
Has Impax Laboratories been receiving favorable news coverage?
Press coverage about IPXL stock has been trending positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Impax Laboratories earned a daily sentiment score of 0.36 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 48.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Impax Laboratories?
Shares of IPXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Impax Laboratories' stock price today?
One share of IPXL stock can currently be purchased for approximately $20.20.
How big of a company is Impax Laboratories?
Impax Laboratories has a market capitalization of $1.46 billion and generates $775.79 million in revenue each year. The specialty pharmaceutical company earns $-469,280,000.00 in net income (profit) each year or $0.63 on an earnings per share basis. Impax Laboratories employs 1,257 workers across the globe.
How can I contact Impax Laboratories?
Impax Laboratories' mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company can be reached via phone at 510-476-2000 or via email at [email protected]
MarketBeat Community Rating for Impax Laboratories (IPXL)
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe IPXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Impax Laboratories (NASDAQ:IPXL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
15 Wall Street analysts have issued ratings and price targets for Impax Laboratories in the last 12 months. Their average twelve-month price target is $21.7333, suggesting that the stock has a possible upside of 7.59%. The high price target for IPXL is $35.00 and the low price target for IPXL is $16.00. There are currently 1 sell rating, 8 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.33 | 2.33 | 2.27 | 2.25 |
| Ratings Breakdown: | 1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $21.7333 | $21.4667 | $20.00 | $19.1875 |
| Price Target Upside: | 7.59% upside | 12.98% upside | 13.64% upside | 0.58% downside |
Impax Laboratories (NASDAQ:IPXL) Consensus Price Target History
Impax Laboratories (NASDAQ:IPXL) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Impax Laboratories (NASDAQ:IPXL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Impax Laboratories (NASDAQ IPXL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 90.40%
Impax Laboratories (NASDAQ IPXL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/31/2017 | Michael Nestor | Insider | Sell | 1,130 | $15.00 | $16,950.00 | 106,943 |  |
| 5/17/2017 | Michael Nestor | Insider | Sell | 857 | $16.48 | $14,123.36 | 108,073 | |
| 5/12/2017 | Michael Nestor | Insider | Sell | 700 | $17.11 | $11,977.00 | 115,168 | |
| 8/15/2016 | Leslie Z Benet | Director | Sell | 10,092 | $22.81 | $230,198.52 | 40,225 | |
| 9/11/2015 | Mark A Schlossberg | SVP | Sell | 7,457 | $43.30 | $322,888.10 | 73,588 | |
| 9/10/2015 | Michael Nestor | Insider | Sell | 5,000 | $43.56 | $217,800.00 | 111,833 | |
| 8/31/2015 | Michael Markbreiter | Director | Sell | 28,000 | $41.70 | $1,167,600.00 | 8,200 | |
| 8/27/2015 | Mark A Schlossberg | SVP | Sell | 4,649 | $43.41 | $201,813.09 | 81,045 | |
| 8/27/2015 | Peter R Terreri | Director | Sell | 4,833 | $43.93 | $212,313.69 | 39,787 | |
| 8/26/2015 | Michael Markbreiter | Director | Sell | 19,399 | $42.24 | $819,413.76 | 8,200 | |
| 6/6/2014 | Larry Hsu | Director | Sell | 100,000 | $28.38 | $2,838,000.00 | | |
| 5/27/2014 | Peter R Terreri | Director | Sell | 3,000 | $28.00 | $84,000.00 | | |
| 5/22/2014 | Larry Hsu | Director | Sell | 50,000 | $27.22 | $1,361,000.00 | 409,568 | |
| 5/21/2014 | Larry Hsu | Director | Sell | 3,800 | $26.53 | $100,814.00 | 459,568 | |
| 5/16/2014 | Nigel Fleming | Director | Sell | 1,900 | $25.72 | $48,868.00 | 11,266 | |
| 5/12/2014 | Nigel Fleming | Director | Sell | 1,333 | $26.58 | $35,431.14 | 8,366 | |
| 5/8/2014 | Michael Markbreiter | Director | Sell | 12,500 | $26.44 | $330,500.00 | 9,699 | |
| 5/6/2014 | Larry Hsu | Director | Sell | 219,386 | $26.28 | $5,765,464.08 | 458,568 | |
| 3/11/2014 | Michael Markbreiter | Director | Sell | 4,000 | $27.54 | $110,160.00 | 9,699 | |
| 1/8/2014 | Robert Burr | Director | Sell | 1,500 | $24.31 | $36,465.00 | 43,825 | |
| 11/13/2013 | Robert Burr | Director | Sell | 1,500 | $22.98 | $34,470.00 | 46,825 | |
| 10/9/2013 | Robert Burr | Director | Sell | 1,500 | $20.10 | $30,150.00 | 48,325 | |
| 9/11/2013 | Robert Burr | Director | Sell | 1,500 | $20.87 | $31,305.00 | 49,825 | |
| 8/14/2013 | Robert Burr | Director | Sell | 1,500 | $21.15 | $31,725.00 | 51,325 | |
| 7/10/2013 | Robert L Burr | Director | Sell | 1,500 | $20.26 | $30,390.00 | | |
| 6/12/2013 | Robert L Burr | Director | Sell | 1,500 | $18.80 | $28,200.00 | | |
| 5/8/2013 | Robert L Burr | Director | Sell | 1,500 | $16.35 | $24,525.00 | | |
| 5/1/2013 | Peter R Terreri | Director | Sell | 3,450 | $17.39 | $59,995.50 | | |
| 3/12/2013 | Larry Hsu | CEO | Buy | 7,000 | $16.88 | $118,160.00 | | |
| 3/12/2013 | Mark A Schlossberg | SVP | Buy | 1,000 | $16.73 | $16,730.00 | | |
| 2/13/2013 | Robert L Burr | Director | Sell | 1,500 | $19.82 | $29,730.00 | | |
| 11/14/2012 | Robert L Burr | Director | Sell | 1,500 | $19.86 | $29,790.00 | | |
| 8/20/2012 | Nigel Fleming | Director | Sell | 6,000 | $23.99 | $143,940.00 | | |
(Data available from 1/1/2013 forward)
Impax Laboratories (NASDAQ IPXL) News Headlines
| Source: |
|
Impax Laboratories (NASDAQ:IPXL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Impax Laboratories (NASDAQ:IPXL) Income Statement, Balance Sheet and Cash Flow Statement
Impax Laboratories (NASDAQ IPXL) Stock Chart for Friday, April, 20, 2018
Loading chart…
